Menu
Recruiting NCT07291687

tDCS as Treatment for Motor Function

No phase Interventional Progressive Supranuclear Palsy Cortical Basal Ganglionic Degeneration Parkinson Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Transcranial direct current stimulation (TDCS), Stimulation Arm.
Who it may be relevant to
Registry conditions: Progressive Supranuclear Palsy, Cortical Basal Ganglionic Degeneration, Parkinson Disease. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Transcranial Direct Current Stimulation as a Treatment for Motor Function in Participants Living With Progressive Supranuclear Palsy, Corticalbasal Syndrome Degeneration, or Parkinson's Disease

Overview

Previous preliminary results are sufficiently impressive to suggest that tDCS stimulation does have the potential to improve motor function when that ability is trained during stimulation. In the proposed study, the investigation will assess whether walking sessions combined with tDCS lead to improvements in motor function: gait, articulation, eye gaze, and motor dexterity. In addition, the investigators wish to examine if such results can be replicated in people with other conditions, such as cortical basal syndrome, and Parkinson's disease.

Detailed description

Previous preliminary results are sufficiently impressive to suggest that tDCS stimulation does have the potential to improve motor function when that ability is trained during stimulation. In the proposed study, the investigators will assess whether walking sessions combined with tDCS lead to improvements in motor function: gait, articulation, eye gaze, and motor dexterity. In addition, the investigators wish to examine if such results can be replicated in people with other conditions, such as cortical basal syndrome, and Parkinson's disease. The rationale for including people living with these conditions is the overlap in motor and cortical network dysfunction observed across these disorders. All three conditions involve impairment of motor initiation, gait, coordination, and executive motor control due to degeneration in frontal-subcortical pathways. This extension will also allow for comparison of stimulation responsiveness across related diagnostic groups and provide insight into disease-specific factors influencing motor recovery potential.

Previous tDCS studies have found significant results with sample sizes between 10-20 participants for a two-round study comparing training sessions with real tDCS versus sessions done without tDCS. However, the investigators plan to recruit 30 participants living with each condition as this will allow us to examine results per group, but also how the individual groups compare.

Interventions

  • Device Transcranial direct current stimulation (TDCS)
    The Crossover design will enable us to use each participant as their own control.
  • Device Stimulation Arm
    Participants will be exposed to the brain stimulation protocol while undergoing certain motor task during the training sessions.

Primary outcome measures

  • Gait speed [Time frame: Measures collected at three points each round: baseline in week 1, post-treatment at the final stimulation session, and follow-up two weeks after the final session.]
Secondary outcome measures (2)
  • Articulation Quality (Clinician-Rated Speech Production on Word and Sentence Repetition) [Time frame: Measures collected at three points each round: baseline in week 1, post-treatment at the final stimulation session, and follow-up two weeks after the final session.]
  • Eye-Gaze Control (Clinician-Rated Ability to Track a Moving Target) [Time frame: Measures collected at three points each round: baseline in week 1, post-treatment at the final stimulation session, and follow-up two weeks after the final session.]

Eligibility criteria

Inclusion criteria

\- 1. Participants must be able to walk unassisted, or with the assistance of a walker or cane, and be individuals who walk daily.

2\. Participants should have a sufficient level of English to be able to express themselves verbally, be able to read and follow instructions.

Exclusion criteria

  • 3\. Individuals with metal implants within the brain such as shunts will be excluded.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Crossover
Masking
Triple blind
Primary purpose
Treatment

Study locations

Canada · 1 center
  • Baycrest Academy of Health Sciences and Geriatric Research — Toronto

Identifiers

NCT: NCT07291687 · 21-17

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗